Longevity & AgingGLP-1 Drugs Linked to 30% Lower Breast Cancer Risk as Clinical Trial Launches
A large retrospective study of over 111,000 women found that those who used GLP-1 agonist drugs for overweight or obesity had a 30% lower rate of breast cancer detected on imaging compared to non-users. The study, presented at the American Society of Clinical Oncology meeting, joins a growing body of evidence linking GLP-1 drugs like semaglutide to reduced cancer risk across multiple tumor types including leukemia, colon, liver, and endometrial cancers. Researchers are now preparing to launch a large prospective clinical trial within months, targeting high-risk women to formally test whether GLP-1 drugs can prevent breast cancer. While observational data cannot prove causation, the consistency of signals across cancer types is striking.
